Genzyme Board Sued Over Drug Delays, Insider Deals
By Abigail Rubenstein ( December 22, 2009, 7:17 PM EST) -- Members of Genzyme Corp.'s board of directors are the target of a shareholder derivative suit filed on Tuesday alleging that they caused the company to issue misleading statements about its compliance with the U.S. Food and Drug Administration and that they sold $117 million of Genzyme stock based on nonpublic information....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.